Frustrated by the constraints of Earth, a team of California scientists took tumor research to space—and may have discovered a ‘kill switch’ for cancer::With the help of Axiom 3 astronauts on the International Space Station, a cancer “kill switch” drug may make it to clinical trials before year’s end.
This is the best summary I could come up with:
Axiom 3 was slated for splashdown Saturday but has been delayed until Tuesday, at the earliest, due to weather, according to SpaceX, which manufactured the Crew Dragon spacecraft used for the mission.
It wasn’t the first time the team—led by Dr. Catriona H.M. Jamieson, a hematologist and medical professor at the college, as well as the director of its Sanford Stem Cell Institute—sent such samples into space.
It previously launched stem cells on multiple Space X flights and noticed that pre-leukemic changes occurred, unseen during the same timeframe in controls on the ground.
On previous missions, her team noticed that mini tumors sent to space activated the gene before tripling in size in just 10 days, a much faster rate of growth than seen on the ground.
On the last Axiom mission, Jamieson’s team sent up mini tumors treated with two types of anti-cancer medications that block ADAR1 in different ways.
Enthused by the results, Jamieson’s team began work on an experimental drug called rebecsinib that blocks ADAR1 activation in a different way—by preventing it from spawning malignant proteins.
The original article contains 559 words, the summary contains 179 words. Saved 68%. I’m a bot and I’m open source!